catechin has been researched along with Cytokine Release Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bao, J; Cui, M; Gao, D; Li, D; Li, M; Lin, J; Ren, S; Sun, R; Wang, M; Xiao, T; Yang, C; Zhang, L; Zhang, P; Zheng, C; Zhou, H | 1 |
| Bertoldi, M; Campagnari, R; Crupi, R; Cuzzocrea, S; Di Paola, R; Menegazzi, M | 1 |
1 review(s) available for catechin and Cytokine Release Syndrome
| Article | Year |
|---|---|
Protective Effect of Epigallocatechin-3-Gallate (EGCG) in Diseases with Uncontrolled Immune Activation: Could Such a Scenario Be Helpful to Counteract COVID-19?
Topics: Anti-Inflammatory Agents; Antioxidants; Autoimmune Diseases; Betacoronavirus; Catechin; Coronavirus Infections; COVID-19; Cytokine Release Syndrome; Humans; NF-kappa B; Pandemics; Plant Extracts; Pneumonia, Viral; Pulmonary Fibrosis; SARS-CoV-2; Signal Transduction; STAT1 Transcription Factor; STAT3 Transcription Factor | 2020 |
1 other study(ies) available for catechin and Cytokine Release Syndrome
| Article | Year |
|---|---|
Both Baicalein and Gallocatechin Gallate Effectively Inhibit SARS-CoV-2 Replication by Targeting M
Topics: Animals; Antiviral Agents; Catechin; Coronavirus 3C Proteases; COVID-19 Drug Treatment; Cytokine Release Syndrome; Flavanones; Humans; Mice; Molecular Docking Simulation; Pandemics; Protease Inhibitors; SARS-CoV-2; Sepsis | 2022 |